Design stable APIs and module boundaries — contract-first types, consistent errors, boundary validation, additive changes. Load when designing REST or GraphQL endpoints, public module interfaces, component props, or FE/BE contracts. Also triggers on "API design", "interface design", "design the API", "module boundary", "API contract", "define the interface". Complements feature-spec (product layer). Routes breaking retirement to api-deprecation-and-migration when it exists.
日本語の概要は準備中です。原文の説明を表示しています。
dvy1987/agent-loom☆ 32026年8月8日 更新
This skill ensures all code follows security best practices and identifies potential vulnerabilities. Use when implementing authentication or authorization, handling user input or file uploads, or creating new API endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
nimoqup046-collab/agora☆ 32026年3月26日 更新
Azure Monitor Ingestion SDK for Java. Send custom logs to Azure Monitor via Data Collection Rules (DCR) and Data Collection Endpoints (DCE).
日本語の概要は準備中です。原文の説明を表示しています。
nimoqup046-collab/agora☆ 32026年3月26日 更新
Provide comprehensive techniques for penetration testing AWS cloud environments. Covers IAM enumeration, privilege escalation, SSRF to metadata endpoint, S3 bucket exploitation, Lambda code extraction, and persistence techniques for red team operations.
日本語の概要は準備中です。原文の説明を表示しています。
nimoqup046-collab/agora☆ 32026年3月26日 更新
Generate comprehensive, developer-friendly API documentation from code, including endpoints, parameters, examples, and best practices
日本語の概要は準備中です。原文の説明を表示しています。
nimoqup046-collab/agora☆ 32026年3月26日 更新
Maps between gene identifier systems (Ensembl, Entrez, HGNC symbol, UniProt, RefSeq, MANE) using AnnotationDbi, biomaRt, mygene, pyensembl, and Ensembl REST. Encodes Ensembl version stripping with GENCODE _PAR_Y preservation, the Ziemann 2016 Excel autocorrect debacle and Bruford 2020 HGNC renames (SEPT*->SEPTIN*, MARCH*->MARCHF*, MARC*->MTARC*, DEC1->DELEC1), OCT4/POU5F1 alias resolution, biomaRt archive endpoints for release pinning, the `filters` (plural) gotcha, MANE Select for clinical reporting, cross-species orthology via Ensembl Compara / OMA / OrthoDB, and tx2gene construction for tximport. Use when converting gene IDs across systems, handling renamed symbols, building tx2gene, pinning to a specific Ensembl release for reproducibility, or mapping cross-species orthologs.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Bulk-query Ensembl BioMart (and other BioMart instances) for cross-database ID mapping, gene/transcript/exon coordinates, and ortholog tables. Use when batch-converting Ensembl IDs to other namespaces (HGNC, RefSeq, UniProt, Entrez), pulling gene coordinate tables for thousands of genes, building ortholog wide-tables across species, or replacing slow Ensembl REST loops with one-shot bulk export. Encodes BioMart's XML query format, R biomaRt vs Python pybiomart trade-off, mart-vs-dataset hierarchy, and the URL endpoint that's BioMart-specific (separate from rest.ensembl.org).
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Quality control for pooled CRISPR screens covering library representation, Gini index, log-skew, replicate Pearson and Spearman concordance, essentialome precision-recall AUC against CEGv2 (Hart 2017), Cas9 cut-toxicity diagnostics, copy-number amplicon detection (Aguirre 2016 / Munoz 2016), bottleneck propagation through plasmid pool, infection, selection, and endpoint stages, MOI verification, and DepMap-style screen-quality scoring. Use when assessing screen quality before hit calling, deciding whether to repeat or rescue a screen, diagnosing low-confidence hits, choosing between MAGeCK / BAGEL2 / Chronos based on quality grade, picking a normalization strategy from QC signatures, or evaluating whether an in-vivo screen retained adequate library complexity.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Query the Ensembl REST API for gene/transcript/protein lookup, sequence retrieval, comparative genomics (Compara), variant effect prediction (VEP), regulatory features, and cross-species ortholog/paralog calls. Use when pulling Ensembl-native data (Ensembl Gene IDs, version-pinned releases, archive endpoints for reproducibility), gene/transcript/exon structure with stable IDs, or VEP for variant annotation. Encodes the 15 req/sec rate limit, archive (e110.rest.ensembl.org) for reproducibility, Ensembl divisions (vertebrates / plants / fungi / metazoa / bacteria), and the symbol-vs-ID stability problem.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
Assesses RNA-seq data quality specifically for alternative splicing analysis. QC layers include experimental design audit (library prep, read length, depth, replicates), STAR 2-pass cohort-style alignment, junction saturation curves and discovery plateau detection, novel-vs-known junction ratio diagnostics, junction-overhang distribution, splice-site strength scoring (MaxEntScan intrinsic + SpliceAI context-aware), strandedness verification, GENCODE basic vs comprehensive choice, and rRNA contamination screening. Splicing analysis is more demanding than DGE on read length, depth, library prep, alignment strategy, and annotation choice — failures silently bias PSI estimates and inflate novel-junction false positives. Use when evaluating data suitability for splicing analysis, troubleshooting low event detection, or designing sequencing experiments where AS is a primary endpoint.
日本語の概要は準備中です。原文の説明を表示しています。
peacezha/HPClaw☆ 32026年10月11日 更新
A live demo or admin page shipped with every feature whose results the user would otherwise not see. Use when adding a backend endpoint or feature with no UI to see it, when output only shows in logs, the DB, or an agent run, or when the user asks 'how do I test this'.
日本語の概要は準備中です。原文の説明を表示しています。
armanisadeghi/ai-matrx☆ 32026年10月14日 更新
Doctrine for adding a capability INTO a live, existing feature to a world-class bar. Use on 'add X to Y', 'extend Y to support X', a new option, button, setting, endpoint, or tool for Y, or a sub-feature spec to implement. NOT for whole-feature audits or overhauls (use feature-deep-dive).
日本語の概要は準備中です。原文の説明を表示しています。
armanisadeghi/ai-matrx☆ 32026年10月14日 更新
Create Convex queries, mutations, and actions with proper validation, authentication, and error handling. Use when implementing new API endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
waynesutton/waynesutton-ai☆ 22026年9月8日 更新
Convex backend specialist. Use this agent for any code inside a `convex/` directory — function definitions, schemas, indexes, queries, mutations, actions, HTTP endpoints, cron jobs, file storage, auth wiring, and component installation. Knows the object-form function syntax, validator patterns, resource limits, and component ecosystem that generic Claude routinely gets wrong.
日本語の概要は準備中です。原文の説明を表示しています。
waynesutton/waynesutton-ai☆ 22026年9月8日 更新
Generates API documentation for PHP projects. Creates endpoint documentation with parameters, responses, and examples.
日本語の概要は準備中です。原文の説明を表示しています。
MikeCheng1208/BattleTree☆ 22026年7月22日 更新
Generates ADR Action classes for PHP 8.5. Creates single-responsibility HTTP endpoint handlers with PSR-7 support. Includes unit tests.
日本語の概要は準備中です。原文の説明を表示しています。
MikeCheng1208/BattleTree☆ 22026年7月22日 更新
Implement REST APIs in ABP Framework with AppServices, DTOs, pagination, filtering, and authorization. Use when building API endpoints for ABP applications.
日本語の概要は準備中です。原文の説明を表示しています。
MikeCheng1208/BattleTree☆ 22026年7月22日 更新